Aktienanalyse zu Resmed Inc (RMD)RMDResmed Inc

ResMed Inc. is a holding company. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. It also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Resmed Inc is a good buy right now, with a current price of $252.86 and a strong RSI of 87.78 indicating overbought conditions but also strong momentum. The forward P/E ratio stands at 18.52, suggesting reasonable growth expectations, while the gross margin is robust at 58.12%. The main risk is the recent insider selling, with the CEO selling nearly 5,000 shares, which could raise concerns about future performance.

10 analysts cover RMD: 4 rate it Buy, 2 Hold and 4 Sell. The average price target is 294.00.